

Agenda
**Extraordinary Meeting of the Strategic Advisory Group of Experts on
Immunization (SAGE)**
7 July 2009
CCV/CICG, Geneva

Time	Session	Key Issues and Questions regarding Pandemic Flu	
09:00	Welcome - introduction		10 min
09:10	Update on epidemiology and disease burden: Update on epidemiology and disease burden: Sylvie Briand, WHO, 20 min Overview of Pandemic Modelling: Neil Ferguson, Imperial College and WG member, 10 min Discussion: 20 min	Key Issues: - Current situation - Severity in industrialized and developing countries - Pre-existing immunity in elderly populations - Risk factors for severe disease - Forecasting virus drift and potential acquisition of resistance to antivirals - Comparative severity with seasonal flu - Strain circulation and potential replacement of seasonal viruses - Impact of wide-spread circulation on population susceptibility	50 min
10:00	Update on vaccine availability: Presentation: Marie-Paule Kieny, WHO, 20 min Discussion: 20 min	Key Issues: - Update on production status for seasonal vaccine for the Northern hemisphere 09-10 season - Expected seasonal vaccine demand - Mapping of A(H1N1) and seasonal vaccine production plans - Impact of advance purchase and other agreements on vaccine availability -Vaccine availability for UN procurement and purchase by low and middle income countries	40 min
10:40	Coffee	Break	20 min
11:00	Update on vaccine efficacy and safety and regulatory issues: Update on strain availability, growth potential and availability of reagents Wenqing Zhang, WHO, 10 min Timelines for availability of data to	Key Issues: - Regulatory pathways (e.g. mock- up, emergency) and issues - Timelines for licensure - Timelines for availability of immunogenicity, effectiveness and safety data	1hr 10 min

	<p>support licensure and licensing processes and timelines: David Wood, WHO, 10 min</p> <p>Discussion: 20 min</p> <p>Vaccine safety: output of the vaccine safety consultation and of the June GACVS meeting: Karen Midthun, US FDA, WG member, 15 min</p> <p>Discussion: 15 mn</p>	<ul style="list-style-type: none"> - Level of protection - Safety issues, particularly with respect to adjuvanted vaccines, pregnant woman, and infants -Simultaneous seasonal vaccine administration 	
12:10	<p>Update on programmatic Issues:</p> <p>Presentation: Thomas Cherian, WHO, 10 min</p> <p>Discussion: 10 min</p>	<p>Key Issues:</p> <ul style="list-style-type: none"> - Vaccine deployment strategies - Country capacity to deliver - Storage - Use including country plans and co-administration - Availability of syringes 	20 min
12:30	Lunch	Break	1 hr
13:30	Discussion	<p>Key Questions for SAGE:</p> <ul style="list-style-type: none"> - What groups should be immunized with influenza A(H1N1) vaccine? - How much pandemic vaccine will be needed? - Which groups should be immunized first in case of scarcity of vaccine? What order for the next priority groups? -What triggers should countries use to decide on start of vaccination for each group? - What should WHO recommend regarding the production and use of adjuvanted vaccines? - What are the consequences of industrialized countries regulatory decisions for developing countries? -Timelines and consequences of manufacturers switch to A (H1N1) production? -What are the factors to be taken into consideration in a decision to whether or not to interrupt production of A (H1N1) vaccine to 	2 hrs

		<p>produce southern hemisphere or northern hemisphere seasonal vaccine</p> <p>-Impact of those decisions on 2010 seasonal vaccine availability?</p> <p>- Could bivalent H1/H3 seasonal vaccine be used besides trivalent for the northern hemisphere in 2009?</p> <p>- What types of seasonal and A(H1N1) vaccine (e.g. tetravalent) should be recommended for the southern and northern hemispheres 2010 and 2010-11 seasons?</p>	
15:30	Coffee	Break	15 min
15:45	Closed Session for SAGE-WG members		1 hr
16:45	End of meeting		